Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bolkar Sahinler

Interventional Pain Medicine Lubbock, TX Medical Doctor

NPI 1659368793 CMS profile 30280

3419 22Nd St, Lubbock, TX 79410

Open in the dashboard

General payments

$188,447

507 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bolkar Sahinler of Lubbock, TX is reported in the CMS Open Payments database as having received $188,447 across 507 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,889 78
2024 General $138,245 61
2023 General $8,491 85
2022 General $4,172 82
2021 General $1,551 50
2020 General $991 56
2019 General $3,109 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bolkar Sahinler
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Bolkar Sahinler were reported at $31,889. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Bolkar Sahinler Interventional Pain Medicine median Middle half National median
2019 $3,109 $684 $216–$2,079 $163
2020 $991 $382 $122–$1,109 $114
2021 $1,551 $552 $167–$1,554 $132
2022 $4,172 $605 $187–$1,924 $149
2023 $8,491 $671 $195–$1,915 $160
2024 $138,245 $684 $206–$1,837 $164
2025 $31,889 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $171,776 203 payments
  2. Roche Diagnostics Corporation $4,700 2 payments
  3. Abbott Laboratories $3,304 46 payments
  4. Relievant Medsystems, Inc. $1,771 15 payments
  5. Medtronic USA, Inc. $1,623 99 payments
  6. Vertiflex, Inc. $1,553 10 payments
  7. Boston Scientific Corporation $989 20 payments
  8. AbbVie, Inc. $568 36 payments
  9. SI-BONE, Inc. $411 7 payments
  10. Collegium Pharmaceutical, Inc. $357 22 payments
  11. Other $1,395 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Debt forgiveness $164,282 3 payments
  2. Food and Beverage $14,256 479 payments
  3. Travel and Lodging $5,159 22 payments
  4. Consulting Fee $4,700 2 payments
  5. Entertainment $50 1 payment
Products named General payments · program years 2019–2025
  1. VANTA ADAPTIVESTIM $2,639 25 payments
  2. INTELLIS ADAPTIVESTIM $2,250 64 payments
  3. Intracept Pain $1,792 16 payments
  4. Intracept Pain $1,771 15 payments
  5. Intracept Pain $1,771 15 payments
  6. Intracept Pain $1,771 15 payments
  7. Superion ISS $1,553 10 payments
  8. INTELLIS $1,453 85 payments
  9. PROCLAIM $1,305 12 payments
  10. SYNCHROMEDII $1,192 44 payments
  11. Other $7,273 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

10,388

Median for Interventional Pain Management: 1,220

Drug cost

$416,020

Median for Interventional Pain Management: $39,344

Branded share of claims

58.7%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 4,235 $120,852
Nucynta Tapentadol Hcl Brand 33 $46,491
Oxycontin Oxycodone Hcl Brand 77 $34,359
Fentanyl Generic 272 $25,193
Xtampza Er Oxycodone Myristate Brand 50 $24,462
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 760 $23,649
Nucynta Er Tapentadol Hcl Brand 19 $17,124
Morphine Sulfate Er Morphine Sulfate Brand 517 $14,616
Gabapentin Generic 879 $13,008
Pregabalin Generic 573 $12,356

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$391,701

Of which drugs: $6,155

Medicare patients

924

Average age 75

Services billed

4,329

528 women, 396 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Diabetes 28%
Chronic kidney disease 21%
Depression 20%
Osteoporosis 20%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 15 78 $4,485
Injection, methylprednisolone acetate, 80 mg J1040 Office 36 83 $511
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 28 320 $91
Injection, fentanyl citrate, 0.1 mg J3010 Office 21 48 $33
Injection, methylprednisolone acetate, 1 mg J1010 Office 80 149 $14
Injection, midazolam hydrochloride, per 1 mg J2250 Office 21 48 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
  • Collegium Pharmaceutical, Inc. $48
$48 50 —
QULIPTA
  • AbbVie, Inc. $20
$20 — —
UBRELVY
  • AbbVie, Inc. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

507 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record